16 April 2024
Fusion Antibodies
plc
("Fusion" or the
"Company")
Change of
Auditor
Fusion Antibodies plc (AIM:
FAB), specialists in pre-clinical antibody
discovery, engineering and supply for both therapeutic drug and
diagnostic applications, announces the
appointment of Kreston Reeves LLP as the Company's new external
auditor for the financial year ended 31 March 2024.
PricewaterhouseCoopers LLP, the
Company's outgoing external auditor, has confirmed to the
Company that there are no matters connected with its ceasing to
hold office that need to be brought to the attention of the members
or creditors of the Company for the purposes of section 519 of the
Companies Act 2006.
Enquiries:
|
Fusion Antibodies plc
|
www.fusionantibodies.com
|
|
Adrian Kinkaid, Chief Executive
Officer
Stephen Smyth, Chief Financial
Officer
|
Via
Walbrook PR
|
|
|
|
|
Allenby Capital Limited
|
Tel: +44
(0)20 3328 5656
|
|
James Reeve/Vivek Bhardwaj
(Corporate Finance)
Tony Quirke/Joscelin Pinnington
(Sales and Corporate Broking)
|
|
|
|
|
|
|
|
|
Shard Capital Partners LLP
|
|
|
Damon Heath (Joint
Broker)
|
Tel: +44
(0)207 186 9952
|
|
|
|
|
|
|
|
Walbrook PR
|
Tel: +44
(0)20 7933 8780 or fusion@walbrookpr.com
|
|
Anna Dunphy
|
Mob: +44
(0)7876 741 001
|
|
|
| |
About Fusion Antibodies plc
Fusion is a Belfast based contract
research organisation ("CRO") providing a range of antibody
engineering services for the development of antibodies for both
therapeutic drug and diagnostic applications.
The Company's ordinary shares were
admitted to trading on AIM on 18 December 2017. Fusion provides a
broad range of services in antibody generation, development,
production, characterisation and optimisation. These services
include antigen expression, antibody production, purification and
sequencing, antibody humanisation using Fusion's proprietary
CDRx TM platform and the production of
antibody generating stable cell lines to provide material for use
in clinical trials. Since 2012, the Company has successfully
sequenced and expressed over 250 antibodies and successfully
completed over 200 humanisation projects and has an international,
blue-chip client base, which has included eight of the top 10
global pharmaceutical companies by revenue.
The Company was established in 2001
as a spin out from Queen's University Belfast. The Company's
mission is to enable pharmaceutical and diagnostic companies to
develop innovative products in a timely and cost-effective manner
for the benefit of the global healthcare industry. Fusion
Antibodies provides a broad range of services in antibody
generation, development, production, characterisation and
optimisation.
Fusion Antibodies growth strategy is
based on combining the latest technological advances with cutting
edge science to deliver new platforms that will enable Pharma and
Biotech companies get to the clinic faster, with the optimal drug
candidate and ultimately speed up the drug development
process.
